FINWIRES · TerminalLIVE
FINWIRES

ウェドブッシュ証券によると、AMCエンターテインメントは2026年に市場シェアを拡大する見込み。

By

-- ウェドブッシュ証券は水曜日の調査レポートで、AMCエンターテインメント（AMC）は北米のプレミアムスクリーン展開と英国および欧州連合における事業拡大計画により、2026年には市場シェアを拡大する態勢が整っていると述べた。 ウェドブッシュ証券は、AMCエンターテインメントが今後数四半期にわたってより安定した新作公開から恩恵を受ける見込みであり、債務返済を優先していることから、同社株に対して引き続き強気の見方を示している。 第1四半期の業績に言及し、同証券は、AMCエンターテインメントが観客一人当たりの収益を継続的に伸ばしており、過去3四半期の国内観客一人当たりの収益は24ドル、海外観客一人当たりは約18ドルで、パンデミック前の水準と比較して約30%増加していると指摘した。 ウェドブッシュ証券は、「観客数と観客一人当たりの収益が緩やかに回復するにつれて、AMCのEBITDA（金利・税金・減価償却費控除前利益）マージンは今後2～5年以内に13～16%に上昇すると予想している」と述べた。 ウェドブッシュはAMCエンターテインメントの投資判断を「アウトパフォーム」に据え置き、目標株価を3ドルとした。

Price: $1.63, Change: $+0.04, Percent Change: +2.52%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL